Therefore, although the mechanism of GDF15 in pulmonary fibrosis is not yet clear, current evidence and technology enable its application as a biomarker for the diagnosis and prognosis of IPF and show its potential as a therapeutic target for IPF. This evidence concerns the gene GDF15 and idiopathic pulmonary fibrosis.